News

Oral treatment with Gilenya (fingolimod) is more effective than Avonex (interferon beta-1a) for controlling brain lesion activity and brain volume loss in children with pediatric-onset multiple sclerosis (POMS), two-year results of the PARADIGMS study show. That means Gilenya provides an effective treatment option for…

Older age, a greater number of health conditions, and prior hospital admissions are associated with more hospitalizations due to all causes among people with multiple sclerosis (MS). However, MS-related hospitalizations decrease as patients age, and are less frequent among women, according to a study analyzing more than two decades…

Sexual dysfunction is prevalent among women with multiple sclerosis (MS), and one way physicians can help improve their patients’ quality of life is to ask them about the problem. That finding is detailed in the study “Sexual dysfunction in women with multiple sclerosis: prevalence and impact on…

About 85% of people with multiple sclerosis (MS) using cannabis find it to be helpful for pain, and 79% find it eases spasticity, a new study reports. The study, “Cannabis use in people with multiple sclerosis and spasticity: A cross-sectional analysis,” was published in…

The risk of invasive cancer may be slightly higher in multiple sclerosis (MS) patients treated with Gilenya (fingolimod) compared with those treated with rituximab, and with people from the general population, a Swedish study suggests. The study, “Cancer Risk for Fingolimod, Natalizumab, and Rituximab…

A new test involving a virtual reality simulation was able to detect balance issues in patients with multiple sclerosis (MS), potentially allowing doctors to identify whether a patient is at risk of falling despite having no apparent problems with walking, according to new research. The results of the study,…

A little over 20 years ago, Montel Williams learned once and for all that he had multiple sclerosis (MS). But that determination should have happened long before then, said the well-known TV personality — who’s made fighting the neurodegenerative disease his life’s mission. Williams, 63, was the star attraction…

An investigational therapy that uses nanocrystals of gold to help the brain repair itself represents a breakthrough in the multiple sclerosis (MS) field, says Clene Nanomedicine‘s chief medical officer Robert Glanzman. Glanzman, MD, recently presented promising results at the ACTRIMS Forum 2020 indicating that Clene’s lead…

A short-chain fatty acid produced by gut bacteria helps to counteract inflammatory responses in multiple sclerosis (MS) by promoting greater numbers of regulatory immune cells, a study reports. But the bacterial composition of the gut (its microbiome) of MS patients is deficient in bacteria that produce this acid —…

Monthly under-the-skin injections of Novartis’ investigational candidate ofatumumab show promise as a convenient, effective, and safe therapeutic option for people with relapsing multiple sclerosis (MS). Data from the ASCLEPIOS and APLIOS clinical trials showed that ofatumumab — currently under regulatory review for possible approval in the U.S. and Europe…

MedDay Pharmaceuticals‘ MD1003 did not ease functional disability or its progression in patients with non-active progressive multiple sclerosis, Phase 3 clinical trial data shows. The SPI2 Phase 3 study (NCT02936037) sought to confirm the positive results of a first Phase 3 trial called MS-SPI…

Sativex (nabiximols), a THC:CBD oral spray, consistently relieves the pain and severity of treatment-resistant spasticity in multiple sclerosis (MS) patients, according to a recent study. An analysis of the Sativex as Add-on therapy Vs. further optimized first-line ANTispastics (SAVANT) study revealed that Sativex, used in…

Ponesimod may soon be a new oral therapy for people with relapsing multiple sclerosis (MS) in Europe, and a filing for its approval in the U.S. is likely within weeks. Janssen Pharmaceuticals, its developer, submitted an application to the European Medicines Agency (EMA) in early March, a first ponesimod filing…

Starting treatment with a disease-modifying therapy (DMT) reduces blood levels of neurofilament light chain (NfL) — a potential biomarker of disease progression and activity — to varying degrees depending on the therapy used, according to a large real-world study of patients with relapsing-remitting multiple sclerosis (RRMS). The findings support…

The Multiple Sclerosis Association of America (MSAA) is offering a host of educational activities on wellness strategies that address both the mind and body in its efforts to mark Multiple Sclerosis Awareness Month. Each year, a month is set aside to heighten awareness of multiple sclerosis (MS),…

As multiple sclerosis (MS) patients live longer, researchers have observed similarities between changes in their brains and in the brains of Alzheimer‘s patients, a study found. Understanding whether these changes are the result of worsening MS-related neurodegeneration or co-occuring (comorbid) Alzheimer’s disease will help guide better treatment…

The Partners Multiple Sclerosis Center at Brigham and Women’s Hospital has joined BrainStorm Cell Therapeutics in a Phase 2 trial exploring the safety and efficacy of NurOwn in the treatment of progressive multiple sclerosis (MS). This is the fifth and final clinical site participating in…

An multi-sensor band worn on the arm or leg, called Myo, can capture and relay difficulties with limb movement due to multiple sclerosis (MS) with an accuracy that mirrors gold standard measures of disability, like the Expanded Disability Status Scale (EDSS), a study reports. These findings support the…

Health Canada has approved Novartis‘s Mayzent (siponimod) for the treatment of adults with active secondary progressive multiple sclerosis (SPMS) to delay the progression of physical disability. Active disease is determined either by the presence of relapses or magnetic resonance imaging features characteristic of inflammatory activity. Multiple sclerosis (MS)…

What science has told us about how diet might influence a person’s risk of multiple sclerosis and a patient’s disease course was the topic of discussion at a recent MS conference. Ellen Mowry, MD, a researcher and professor of neurology at John Hopkins, also reviewed some of the dietary…

The National Multiple Sclerosis Society (NMSS) is marking Multiple Sclerosis Awareness Week, March 8-14, by sharing patients’ stories and encouraging participation in fundraising and advocacy efforts. Each year, a week is set aside to heighten awareness of multiple sclerosis (MS), a neurodegenerative disorder that affects nearly 1 million people in…

Janssen has submitted an application to the European Medicines Agency (EMA) asking that ponesimod be approved as an oral treatment for adults with relapsing multiple sclerosis (MS) in the European Union. Ponesimod (formerly ACT-128800) is an experimental treatment that targets the sphingosine-1-phosphate receptor…

In recognition of Rare Disease Day Feb. 29, Bionews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the #WhatMakesMeRare campaign was aimed at uplifting people with rare diseases by encouraging them to share their stories and perspectives. The…

Treatment for two months with N-acetylcysteine, or NAC — a natural molecule that enhances the levels of antioxidants — significantly improved metabolic activity in certain brain regions among people with multiple sclerosis (MS), a small clinical study reports. This increase in metabolic activity was accompanied by improvements…

Modulating the bacteria that reside in the gut by treating multiple sclerosis (MS) patients with probiotics, fecal transplants, or gut-related microRNAs may help to ease inflammation and disease severity, researchers with Brigham and Women’s Hospital suggest. Howard Weiner, MD, a group leader at the hospital, presented his team’s findings on…

A signaling molecule of the immune system called interleukin 13 (IL-13) may modulate the function of key immune cells involved in multiple sclerosis (MS), and their migration through the barrier that protects the brain and spinal cord. IL-13 is an “attractive molecule” and a potential avenue for treating MS,…

Emerald Health Pharmaceuticals’ investigational cannabidiol-derived EHP-101 continues to show potential to ease inflammation and myelin loss (demyelination) — a hallmark of multiple sclerosis (MS) — according to data from healthy volunteers and a mouse model of MS. The data support the advance of EHP-101’s clinical development into…

Ozanimod — an investigational oral therapy up for approval to treat relapsing multiple sclerosis (MS) — lowers the number of white blood cells circulating in the blood, supporting its ability to ease inflammation in the brain and spinal cord. But this treatment also does not affect all…

CorTechs Labs presented new data indicating that machine learning models based on magnetic resonance imaging (MRI) of the brain may aid in the early diagnosis of multiple sclerosis (MS). Company representatives, joined by other experts, also released updated recommendations for a standardized…

Using a patient-friendly autoinjector pen to take monthly doses of ofatumumab — an investigational B-cell therapy for relapsing multiple sclerosis (MS) — is bioequivalent to delivering it via a prefilled syringe, and would allow self-administration of the treatment at home, a study shows. Equal effects…